Novel combination therapy with phenformin enhances the effects of lenvatinib in hepatocellular carcinoma via AMPK-mediated PDGFRβ degradation
Our study reports a novel combined therapy using phenformin and lenvatinib, which can increase the sensitivity of HCC cells to lenvatinib via AMPK-mediated PDGFRβ degradation. Hence, this treatment strategy may provide a personalized approach for treating HCC patients with high PDGFRβ expression and facilitate the development of basic and clinical research on the use of lenvatinib for the treatment of HCC.
Authors
- Cangcang Xu (ORCID: https://orcid.org/0000-0002-8086-6212)
- Mei Peng (ORCID: https://orcid.org/0009-0002-7683-1268)
- Zhuan Li (ORCID: https://orcid.org/0000-0002-1310-4584)
- Liwei Xie (ORCID: https://orcid.org/0000-0002-4747-1753)
- Weimin Wang (ORCID: https://orcid.org/0000-0002-4789-6399)
- Duo Li (ORCID: https://orcid.org/0000-0001-8278-8011)
- Qi Zhong (ORCID: https://orcid.org/0009-0008-8530-4973)
- Huaying Wu
- Di Xiao (ORCID: https://orcid.org/0000-0003-3686-8226)
- Xiaoping Yang
Institutions
- Hunan University of Traditional Chinese Medicine (CN)
- Hunan Normal University (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1186/s12935-025-04012-5
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Hunan Normal University